4.7 Review

Pain in amyotrophic lateral sclerosis

Journal

LANCET NEUROLOGY
Volume 16, Issue 2, Pages 144-157

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/s1474-4422(16)30358-1

Keywords

-

Funding

  1. European Union - Italian Ministry of Health
  2. European Union - Italian Ministry of Education, University and Research
  3. Italian Ministry of Health
  4. European Commission
  5. Compagnia di San Paolo
  6. Agenzia Italiana per la Ricerca sulla SLA (ARISLA)
  7. Fondazione Vialli e Mauro Onlus
  8. Associazione Piemontese per l'Assistenza alla SLA (APAS LA)
  9. ARISLA
  10. European Union - Italian Ministry of Health
  11. European Union - Italian Ministry of Education, University and Research
  12. Italian Ministry of Health
  13. European Commission
  14. Compagnia di San Paolo
  15. Agenzia Italiana per la Ricerca sulla SLA (ARISLA)
  16. Fondazione Vialli e Mauro Onlus
  17. Associazione Piemontese per l'Assistenza alla SLA (APAS LA)
  18. ARISLA
  19. Economic and Social Research Council [ES/L008238/1] Funding Source: researchfish
  20. ESRC [ES/L008238/1] Funding Source: UKRI

Ask authors/readers for more resources

Pain is a largely neglected symptom in patients with amyotrophic lateral sclerosis (ALS) although it is reported by most of these patients. It occurs at all stages of the disease and can be an onset symptom preceding motor dysfunction. Pain is correlated with a deterioration in patients' quality of life and increased prevalence of depression. In the later stages of ALS, pain can be severe enough to require increased use of sedative and analgesic drugs, and is among the events that predict clinical deterioration and death. The site of pain depends on the pain type or underlying mechanism (eg, painful cramps, nociceptive pain, or neuropathic pain). Given the multifactorial nature of pain in patients with ALS, different treatments have been suggested, ranging from non-steroidal anti-inflammatory drugs, drugs for neuropathic pain, opioids, and cannabinoids, to physical therapy strategies and preventive assistive devices. Further understanding of the pathophysiology is crucial to drive assessment in clinical trials of therapeutic strategies targeted at specific mechanisms and studies of individualised therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available